Doxycycline vs Placebo at 12 Weeks in Patients With Mild Thyroid-Associated Ophthalmopathy

医学 安慰剂 强力霉素 不利影响 内科学 生活质量(医疗保健) 随机对照试验 外科 儿科 抗生素 病理 替代医学 护理部 微生物学 生物
作者
Yuan Pan,Yuxi Chen,Jian Zhang,Miaoli Lin,Guang‐Ming Liu,Xueliang Xu,Xianqun Fan,Yong Zhong,Qing Li,Siming Ai,Wen Xu,Jia Tan,Huifang Zhou,Dongdong Xu,Huiying Zhang,Bei Xu,Sha Wang,Junjie Ma,Shuo Zhang,Linyang Gan
出处
期刊:JAMA Ophthalmology [American Medical Association]
卷期号:140 (11): 1076-1076 被引量:8
标识
DOI:10.1001/jamaophthalmol.2022.3779
摘要

Importance Mild thyroid-associated ophthalmopathy (TAO) negatively impacts quality of life, yet no clinical guidelines for its treatment are available. Existing evidence supports the use of doxycycline in treating mild TAO. Objective To evaluate the short-term (12 weeks) efficacy of doxycycline in treating mild TAO. Design, Setting, and Participants In this placebo-controlled multicenter randomized double-masked trial, 148 patients were assessed for eligibility. After exclusions (patients who were pregnant or lactating, had an allergy to tetracyclines, or had uncontrolled systematic diseases), 100 patients with mild TAO (orbital soft tissue affected mildly) at 5 centers in China were enrolled from July 2013 to December 2019 and monitored for 12 weeks. Interventions Participants were randomly assigned 1:1 to receive doxycycline (50 mg) or placebo once daily for 12 weeks. Main Outcomes and Measures The primary outcome was the rate of improvement at 12 weeks compared with baseline assessed by a composite indicator of eyelid aperture (reduction ≥2 mm), proptosis (reduction ≥2 mm), ocular motility (increase ≥8°), and Graves ophthalmopathy-specific quality-of-life (GO-QOL) scale score (increase ≥6 points). Adverse events were recorded. Results A total of 50 participants were assigned to doxycycline and 50 to placebo. The mean (SD) age was 36.7 (9.1) years; 75 participants (75.0%) were female and 100 (100.0%) were Asian. Medication compliance was checked during participant interviews and by counting excess tablets. At week 12, the improvement rate was 38.0% (19 of 50) in the doxycycline group and 16.0% (8 of 50) in the placebo group (difference, 22.0%; 95% CI, 5.0-39.0; P = .01) in the intention-to-treat population. The per-protocol sensitivity analysis showed similar results (39.6% [19 of 48] vs 16.0% [8 of 50]; difference, 23.6%; 95% CI, 6.4-40.8; P = .009). No adverse events other than 1 case of mild gastric acid regurgitation was recorded in either group. Conclusions and Relevance The results of this study indicate that oral doxycycline, 50 mg daily, resulted in greater improvement of TAO-related symptoms at 12 weeks compared with placebo in patients with mild TAO. These findings support the consideration of doxycycline for mild TAO but should be tempered by recognizing the relatively short follow-up and the size of the cohort. Trial Registration ClinicalTrials.gov Identifier: NCT02203682
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
yhn发布了新的文献求助10
刚刚
刚刚
刚刚
漠尘完成签到,获得积分10
1秒前
1秒前
1秒前
2秒前
3秒前
3秒前
Qing发布了新的文献求助10
3秒前
3秒前
3秒前
Xueanliu发布了新的文献求助10
4秒前
wangQ发布了新的文献求助10
4秒前
6秒前
稳重电话发布了新的文献求助10
6秒前
8秒前
Felix发布了新的文献求助10
8秒前
8秒前
年轻烨霖发布了新的文献求助10
8秒前
天天向上发布了新的文献求助10
8秒前
zkb发布了新的文献求助30
9秒前
entscholar完成签到,获得积分10
10秒前
10秒前
11秒前
Owen的应助被强强采纳,获得10
11秒前
小蘑菇的应助被科研通管家采纳,获得10
11秒前
Owen的应助被科研通管家采纳,获得10
11秒前
所所的应助被科研通管家采纳,获得10
11秒前
大丑橘粑粑柑公主完成签到,获得积分10
11秒前
大个的应助被科研通管家采纳,获得10
11秒前
爆米花的应助被科研通管家采纳,获得10
11秒前
科研通AI2S的应助被科研通管家采纳,获得10
11秒前
追风少年的应助被科研通管家采纳,获得30
12秒前
12秒前
情怀的应助被科研通管家采纳,获得10
12秒前
情怀的应助被科研通管家采纳,获得10
12秒前
Lucas的应助被科研通管家采纳,获得10
12秒前
奔跑的应助被科研通管家采纳,获得10
12秒前
乐乐的应助被科研通管家采纳,获得10
12秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 2000
Handbook of Sport Coaching Research 1000
Orthognathic Surgery - 2 Volume Set 500
高分子基功能界面水蒸发材料与应用研究 500
外场增强的水汽发电研究 500
基于结构调控的功能化水诱导发电材料与器件研究 500
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8193599
求助须知:如何正确求助?哪些是违规求助? 9579723
关于积分的说明 21867157
捐赠科研通 7793198
什么是DOI,文献DOI怎么找? 3437314
关于科研通互助平台的介绍 2560725
邀请新用户注册赠送积分活动 2484193